Mr. Zami Aberman joined Pluristem in September 2005, and redirected the Company's strategy towards cellular therapeutics to become one of the global leaders in the industry. Mr. Aberman's vision to use the maternal portion of the placenta as a cell source for Pluristem’s products, combined with Pluristem's 3D culturing technology, led to the development of the Company's unique therapies. In 2013 the World Stem Cells Regenerative Medicine Congress ranked Mr. Aberman as one of the 50 most influential people in the stem cells space. Prior to Pluristem, Mr. Aberman had a 30 year career as a senior executive in the high-tech industry with multiple companies in Israel, the U.S., Europe, Japan and Korea. Previous roles include Chairman of VLScom Ltd., a private company specializing in video compression for HDTV and video over IP; Director of Ori Software Ltd., a company involved in data management; President and CEO of Elbit Vision Systems (EVSNF.OB), which supplies inspection systems for the microelectronics industry; President and CEO of Netect Ltd., a company specializing in the field of internet security software; Co-Founder, President and CEO of Associative Computing Ltd., which developed an associative parallel processor for real-time video processing; Chairman of Display Inspection Systems Inc., a company specializing in laser based inspection machines; and President and CEO of Robomatix Technologies Ltd. (RBMXF.OB). In addition to his current role at Pluristem, Mr. Aberman serves as the Chairman of Rose Hitech Ltd., a private investment company In 1992, Mr. Aberman was awarded the Rothschild Prize for excellence in his field from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.
Mr, Yaky Yanay was appointed as President from February 2014 and as our Co-CEO from March 2017. Mr. Yanay served in variety of executive positions in Pluristem since 2006 including Chief Financial Officer, Chief Operating Officer and Executive Vice President. Mr. Yanay is Co-Chairman of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s high tech and life science industries. Yanay is representing Israel’s life sciences industry and has served on the Board of Directors of IATI for the past five years. Mr. Yanay also founded and served as Chairman of “The Israeli Life Science Forum” Before joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd., a public company. Prior to that Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel.
Mr. Mark Germain has served as a Director on the Board of Directors since May 17, 2007. For more than the past five years, Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries.
He has been involved as a founder, director, Chairman of the Board, and/or investor in over twenty companies in the biotech field, and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law. From 1986 to 1991 he served in senior executive capacities, including as president of a public company that was sold in 1991, at which time he entered the biotech field.
In addition to being Director on the Board of Pluristem, Mr. Germain is a Managing Director at The Aentib Group, a global boutique advisory and investment firm, serves as Vice-Chairman of BiondVax Pharmaceutical's Board of Director, as well as a Director of the following publicly traded companies: Wellford Real Properties, Inc., Stem Cell Innovations, Inc., and Collexis Holdings, Inc. He is also a co-founder and director of a number of private companies in the biotechnology field.
Mrs. Hava Klemperer Meretzki, Adv. is a partner in the law firm of Ben-Noun Meretzki in Haifa, Israel. She specializes in civil, trade and labor law and is presently Vice-Chairman for the National Council of the Israel Bar Association. She previously was a Director of the Israel Electric Company. Ms. Meretzki received a Bachelor's Degree in Law from the Hebrew University in 1991, and in 1992, was admitted to the Israel Bar Association.
Mr. Doron Shorrer (CPA, Israel) was Chairman of the Board of Phoenix Insurance Company, one of the largest insurance companies in Israel and Mivtachim Pension Benefit Group, the largest pension fund in Israel, managing $15 billion. Before assuming these positions, Mr. Shorrer held senior appointments that included: Arbitrator at the Claims Resolution Tribunal for Dormant Accounts in Switzerland; Economic and Financial Advisor, Commissioner of Insurance and Capital Markets for the State of Israel; Member of the Board of Directors of "Nechasim" of the State of Israel; Member of the Committee for the Examination of Structural Changes in the Capital Market (The Brodet Committee); General Director of the Ministry of Transport; Co-Founder and Director of an accounting firm having three branches (Jerusalem, Tel-Aviv, Haifa); Member of the Lecture Staff of the Amal School Chain; Chairman of a Public Committee for Telecommunications; and Economic Consultant to the Ministry of Energy.
Among many areas of expertise, Mr. Shorrer formulates, implements and administers business planning in the private and institutional sector. Additionally, Mr. Shorrer consults on economic, accounting and taxation issues to a large audience, ranging from private concerns to government ministries. Mr. Shorrer holds a B.A. in Economics and Accounting and an M.A. in Business Administration, with a specialization in finance and banking from the Hebrew University of Jerusalem. He is a Certified Public Accountant (ISR).
Mr. Isaac Braun was appointed a Director of Pluristem on July 6, 2005. Mr. Braun is a business veteran with entrepreneurial, industrial and manufacturing experience. He has been a co-founder and board member of several hi-tech start-ups in the areas of e-commerce, security, messaging, search engines and biotechnology. Mr. Braun advises private companies on raising financing and business development.
Mr. Israel Ben-Yoram was appointed a director of Pluristem on January 26, 2005. Mr. Ben-Yoram has been a director and partner in the accounting firm of Mor, Ben-Yoram and Partners in Israel from 1985 to the present. This accounting firm currently employs over 15 employees in the field of auditing, consulting, and associated projects. Since 1992, Mr. Ben-Yoram has served as a shareholder and the head director of Mor, Ben-Yoram Ltd., a private company in Israel, in parallel with the operation of the Mor, Ben-Yoram and Partners accounting firm. This company provides management services, economic consulting services and other professional services to businesses. Mr. Ben-Yoram received a B.A. in accounting from the University of Tel Aviv, an M.A. in Economics from the Hebrew University of Jerusalem, an L.L.B. and an M.B.A. from Tel Aviv University and an L.L.M. from Bar-Ilan University.
Mr. Nachum Rosman is an expert in finance, management and organization. He has held Chief Executive and CFO positions in Israel, USA and England. He has operated in high-tech global companies in software and business. In these jobs he was responsible for finance management, fund-raising, acquisitions, technology sales, preparation of financial reports for due diligences, etc.
Mr. Rosman serves as a consultant to start-up companies in financing, strategy and reorganization. He serves as the CEO of Multiview Ltd, a company he co-founded in 1999. He serves as a director at Zoomix data mastering and Knolan.
Mr. Rosman was a director actively involved in the sale of New Dimension Ltd. to B.M.C. Inc. for $ 675 million. Prior to that he held a Co-CEO position in R.T.S. Ltd. (Virinet Ltd.), where he participated in the IPO on NASDAQ.
Dr. Moria Kwiat is a Research Fellow in the Department of Material and NanoScience, Faculty of Chemistry at Tel Aviv University. During her studies she has gained a broad scientific experience in inter-disciplinary fields, and currently she is working on the development of a new generation of biosensors based on Nano-materials. Mrs. Kwiat holds a B.Sc. and M.Sc. in Biotechnology from the Department of Molecular Microbiology and Biotechnology at Tel Aviv University, and a Ph.D. in Nano-Biotechnology from the Faculty of Exact Sciences at Tel Aviv University.
Dr. Roger Jeffs has joined Pluristem’s strategic advisory board to advise on clinical and commercial strategies for the Company’s cell therapy programs.
Dr. Jeffs is Former Co-CEO of United Therapeutics, led the company from its founding until 2016 and led Amgen’s Neupogen clinical programs.